Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.
| AOD-9604 | Tesofensine | |
|---|---|---|
| Category | Growth Factors | Pharmaceuticals |
| Standard Dose | Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach. | Research indicates 0.25-0.5 mg daily via oral administration. |
| Timing | Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect. | Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia. |
| Cycle Duration | 12-20 week cycles. | 12-24 week cycles. Monitor cardiovascular parameters throughout. |
| Evidence Level | moderate_human | moderate_human |
AOD-9604 is a synthetic 16-amino acid fragment (residues 176-191) of the C-terminal domain of human growth hormone with a tyrosine substitution at the N-terminus. It selectively stimulates lipolysis by upregulating beta-3 adrenergic receptors in adipose tissue while inhibiting lipogenesis. It modulates lipid and glucose metabolism through beta-adrenergic and AMPK-related pathways without influencing IGF-1 activity, growth, or insulin sensitivity — retaining GH's fat-burning properties without its growth-promoting effects.
Research indicates 250-300 mcg daily via subcutaneous injection, administered in the morning on an empty stomach.
Morning administration on empty stomach, at least 30 minutes before eating. Fasted state enhances lipolytic effect.
12-20 week cycles.
Tesofensine (NS2330) is a triple monoamine reuptake inhibitor with affinity for dopamine (DAT), serotonin (SERT), and norepinephrine (NET) transporters. It suppresses appetite through indirect stimulation of alpha-1 adrenoceptor and dopamine D1 receptor pathways, reflecting additive effects of increased NE and DA activity. Tesofensine is a dual-action drug with both anorexigenic properties (appetite suppression) and metabolic properties (increased energy expenditure), silencing GABAergic hypothalamic neurons in the lateral hypothalamus.
Research indicates 0.25-0.5 mg daily via oral administration.
Morning dosing only. Avoid afternoon/evening dosing due to stimulant properties and potential insomnia.
12-24 week cycles. Monitor cardiovascular parameters throughout.
Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.
Get Your Free Protocol →or take the assessment →